GLP-1 Receptor Agonist

Semaglutide

GLP-1 Signaling • Once-Weekly SubQ

Semaglutide is a long-acting GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. It reduces appetite, slows gastric emptying, improves glucose-dependent insulin release, suppresses glucagon, and has extensive human clinical-trial evidence.

Routes

SubQ Injection

Compound type

Long-acting GLP-1 analog

Regulatory status

Approved products available

Last reviewed

October 16, 2026

At a glance

Semaglutide Quick Reference

Starting dose: Members only
Sign in to view dosing details.
Weight-management maintenance: Members only
Sign in to view dosing details.
Class: GLP-1 receptor agonist
Single-receptor incretin therapy
Half-life: Approximately 7 days
Supports once-weekly SubQ dosing

Overview

What Is Semaglutide?

Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist. It mimics GLP-1, a hormone naturally released from the small intestine after eating that helps regulate appetite, gastric emptying, insulin secretion, and glucagon release.

The molecule is engineered to resist rapid enzymatic breakdown and bind strongly to albumin, producing an approximate half-life of seven days. This supports once-weekly subcutaneous dosing.

Unlike dual- or triple-receptor agonists, semaglutide acts through the GLP-1 receptor alone. Its effects on appetite, insulin secretion, glucagon, and gastric emptying are therefore attributable to a well-characterized single incretin pathway.

Mechanism

Semaglutide Mechanism of Action

Appetite and satiety

GLP-1 receptor signaling affects brain pathways involved in hunger and fullness, helping reduce food intake and meal size.

Gastric emptying

Semaglutide delays gastric emptying. This can contribute to fullness and also affects gastrointestinal tolerability and the absorption timing of oral medicines.

Glucose-dependent signaling

Semaglutide increases insulin secretion and suppresses glucagon when glucose is elevated. Hypoglycemia risk rises when combined with insulin or sulfonylureas.

Long-acting exposure

Resistance to rapid enzymatic breakdown and strong albumin binding produce an approximately seven-day half-life, allowing once-weekly injection schedules.

Research findings

Semaglutide Benefits

Semaglutide has one of the strongest clinical-evidence bases in the weight-management category, including large Phase 3 trials and cardiovascular and kidney-outcome studies.

Evidence: large clinical trials and outcome studies

Clinically Significant Weight Loss

In STEP-1, adults without diabetes lost an average of 14.9% of body weight at 68 weeks with 2.4mg weekly versus 2.4% with placebo. Wegovy prescribing information.

Appetite Suppression

GLP-1 signaling in the hypothalamus and brainstem increases satiety, reduces hunger signals, and lowers the reward value of food.

Slower Gastric Emptying

Food leaves the stomach more slowly, which can increase fullness and reduce meal size, but also contributes to nausea, reflux, and gastroparesis risk.

Glucose Control

Semaglutide increases glucose-dependent insulin secretion and suppresses glucagon when blood glucose is elevated.

Cardiovascular Protection

The SELECT trial reported a 20% reduction in major cardiovascular events in adults with overweight or obesity and established cardiovascular disease.

Kidney Outcomes

The FLOW trial reported a 24% reduction in clinically important kidney outcomes in people with type 2 diabetes and chronic kidney disease.

Protocol planning

Semaglutide Dosing Protocol

Members Access Only

Preparation

Semaglutide Reconstitution

Reconstitution Example

5mg vial + 2mL BAC water

Result2.5mg/mL

Reconstitution steps

Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

Add diluent slowly

Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.

Dissolve gently

Swirl or roll the vial until the contents dissolve; do not shake.

Storage

Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.

N=1 reports

Semaglutide Community Experience

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Food often becomes less interesting, making calorie control feel easier and less dependent on willpower.
Many users report smaller portions, less snacking, and fewer cravings within the first several weeks.
Weight loss of approximately 8%–18% over six to twelve months is commonly reported.
Users who maintain resistance training and protein intake report better strength and body-composition outcomes.
Lower doses are sufficient for some people and may produce better adherence with fewer side effects.
Appetite suppression is often strongest for several days after the weekly injection.

Negative & Mixed Reports

Nausea is most common after dose increases and may last one to two weeks at each new dose.
Constipation, reflux, fatigue, food aversion, and difficulty eating enough protein are frequent complaints.
Hair shedding and a gaunt facial appearance may occur with rapid or substantial weight loss.

Stacking & synergy

Semaglutide Stacking & Synergy

These are reported pairings and practical combinations. Introduce changes separately and track the effects of each compound.

Resistance Training + Protein

The most important combination for preserving lean mass. Prioritize regular resistance training and adequate protein while appetite is suppressed.

Semaglutide + BPC-157 / TB-500

No established interaction is known, but claims that BPC-157 reduces semaglutide-related GI symptoms are anecdotal and unsupported by controlled trials.

Semaglutide + CJC-1295 / Ipamorelin

Community users pair this GH-releasing combination with Semaglutide during recomposition-focused fat-loss phases, aiming to support training performance and lean-mass retention. No controlled study has shown that the stack prevents Semaglutide-associated lean-mass loss.

Semaglutide + Tesamorelin

Tesamorelin is known for reducing visceral fat in its approved treatment setting. RUO communities pair it with Semaglutide to combine visceral-fat targeting with systemic appetite suppression, but this combination has not been validated in controlled trials.

Safety notes

Semaglutide Side Effects & Safety

Gastrointestinal effects are common, especially during titration. Slow dose escalation and smaller meals usually improve tolerability, but serious complications can occur.

Seek medical care for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, jaundice, signs of dehydration, severe constipation with abdominal distention, or symptoms of an allergic reaction.

In Published Research

Common: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue.
Less common: reflux, bloating, gas, dizziness, injection-site reactions, and hair loss.
Important risks include gallbladder disease, clinically significant delayed gastric emptying, dehydration-related kidney injury, and possible pancreatitis.

What Users Report

Nausea and constipation are most frequently reported during dose escalation.
Fatigue, low energy, reflux, sulfur burps, and reduced ability to eat enough protein are common complaints.
Rapid weight loss may contribute to hair shedding, facial-volume loss, and reduced strength when nutrition and training are inadequate.

Semaglutide Precautions

Do Not Use If You Have

A personal or family history of medullary thyroid carcinoma.
Multiple Endocrine Neoplasia syndrome type 2.
Known hypersensitivity to semaglutide or product ingredients.
Pregnancy. Semaglutide used for weight reduction should be discontinued when pregnancy is recognized and at least two months before a planned pregnancy.

Use Caution With

A history of pancreatitis, gallstones, gallbladder disease, or severe gastrointestinal disease.
Gastroparesis or persistent delayed gastric emptying.
Kidney disease, especially if vomiting or diarrhea may cause dehydration.
Diabetic retinopathy, particularly when glucose levels may improve rapidly.
Upcoming surgery or anesthesia because delayed gastric emptying may increase aspiration risk.
Drug Interactions: Insulin and sulfonylureas can increase hypoglycemia risk when combined with semaglutide. Delayed gastric emptying may alter the absorption timing of oral medications. Do not combine semaglutide with another GLP-1 receptor agonist or multi-agonist containing GLP-1 activity.
Monitoring: Monitor body weight, waist measurement, gastrointestinal tolerance, hydration, glucose, HbA1c when relevant, kidney function when clinically indicated, gallbladder symptoms, and lean-mass preservation. People with diabetes should monitor for hypoglycemia when using insulin or sulfonylureas.

Regulatory status: FDA-approved semaglutide indications include type 2 diabetes treatment, chronic weight management, cardiovascular-risk reduction, and reduction of kidney-disease progression risk in specific eligible populations. Each branded formulation has its own indication, dose range, and prescribing instructions.

Final verdict

Peptide Protocols Verdict on Semaglutide

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Our opinionated opinion

We view Semaglutide as proven and effective for appetite control and weight loss. It was one of the early game-changers in the GLP-1 space and helped a lot of people get results when options were more limited. However, newer dual and triple agonists have largely surpassed it for most users seeking maximum fat loss and body recomp. Still useful in certain cases or at lower doses, but no longer our top GLP-1 recommendation.

It’s still a solid tool if budget or access is an issue, but we personally prefer the more advanced options for better overall outcomes and fewer limitations, such as Reta or Tirz. Not bad, just no longer the best in class and the Ozempic face you've heard about online is real. No matter which GLP you are taking, you must meet your daily food intake and especially protein goals. This is a non-negotiable in our view.